C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 84 filers reported holding C4 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $598,193 | -19.4% | 321,609 | +19.2% | 0.00% | – |
| Q2 2023 | $741,956 | +45.3% | 269,802 | +65.9% | 0.00% | – |
| Q1 2023 | $510,721 | -68.0% | 162,650 | -39.8% | 0.00% | -100.0% |
| Q4 2022 | $1,594,298 | -42.7% | 270,220 | -14.8% | 0.00% | 0.0% |
| Q3 2022 | $2,780,000 | -2.3% | 317,045 | -15.9% | 0.00% | 0.0% |
| Q2 2022 | $2,844,000 | -64.4% | 377,186 | +14.4% | 0.00% | -66.7% |
| Q1 2022 | $7,995,000 | -27.6% | 329,578 | -3.9% | 0.00% | 0.0% |
| Q4 2021 | $11,038,000 | -40.8% | 342,798 | -17.9% | 0.00% | -50.0% |
| Q3 2021 | $18,647,000 | +22.8% | 417,353 | +4.0% | 0.01% | +20.0% |
| Q2 2021 | $15,188,000 | +56.4% | 401,373 | +52.9% | 0.01% | +66.7% |
| Q1 2021 | $9,708,000 | +191.0% | 262,438 | +160.6% | 0.00% | +200.0% |
| Q4 2020 | $3,336,000 | – | 100,716 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |